HDACi mediate UNG2 depletion, dysregulated genomic uracil and altered expression of oncoproteins and tumor suppressors in B- and T-cell lines

BACKGROUND: HDAC inhibitors (HDACi) belong to a new group of chemotherapeutics that are increasingly used in the treatment of lymphocyte-derived malignancies, but their mechanisms of action remain poorly understood. Here we aimed to identify novel protein targets of HDACi in B- and T-lymphoma cell l...

Descripción completa

Detalles Bibliográficos
Autores principales: Iveland, Tobias S., Hagen, Lars, Sharma, Animesh, Sousa, Mirta M. L., Sarno, Antonio, Wollen, Kristian Lied, Liabakk, Nina Beate, Slupphaug, Geir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137348/
https://www.ncbi.nlm.nih.gov/pubmed/32264925
http://dx.doi.org/10.1186/s12967-020-02318-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137348/
https://www.ncbi.nlm.nih.gov/pubmed/32264925
http://dx.doi.org/10.1186/s12967-020-02318-8

Ejemplares similares